PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. Electronic address: fredrikschjesvold@gmail.com.\', \'Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.\', \'Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece.\', \'Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.\', \'Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.\', \'Department of Hematology and Bone Marrow Transplantation, St John of Dukla Oncology Center of Lublin, Lublin, Poland.\', \'Department of Internal Medicine, University Hospital Brno, Brno, Czech Republic.\', \'Charles University and General Hospital, Prague, Czech Republic.\', \'Department of Hematology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.\', \'Hematology Department, State Budget Healthcare Institution of Moscow, City Clinical Hospital #40 of Moscow Healthcare Department, Moscow, Russia.\', \'Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic; University Hospital Olomouc, Olomouc, Czech Republic.\', \'Chemotherapy of Oncohematology Diseases and Bone Marrow Transplantation Department, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia.\', \'Division of Hematology and Bone Marrow Transplant Center, Hospital Guglielmo da Saliceto, Piacenza, Italy.\', \'4th Department of Medicine - Haematology, Charles University Hospital, Hradec Králové, Czech Republic.\', \'South-Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary.\', \'Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, IDIBAPS, Josep Carreras Research Institute, Hospital Clinic Provincial, Barcelona, Spain.\', \'Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy.\', \'Department of Hematology, University of Patras, Patras, Greece.\', \'Oncopeptides AB, Stockholm, Sweden.\', \'Department of Hemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hemato-oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.\', \'Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain.\', \'Dana-Farber Cancer Institute, Boston, MA, USA.\', \'Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2352-3026(21)00381-110.1016/S2352-3026(21)00381-1
?:doi
?:hasPublicationType
?:journal
  • The Lancet. Haematology
is ?:pmid of
?:pmid
?:pmid
  • 35032434
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35032434>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35032434>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all